Month: April 2023
On April 25, 2023, the US Food and Drug Administration (FDA) announced that Qalsody (tofersen) HAS BEEN APPROVED as a new prescription therapy for the treatment of people with rare…
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for…
Researchers at the VCU Health ALS Clinic found that Black patients in Virginia experienced longer delays to being diagnosed with ALS than white patients. Now, they are focused on finding…
The ALS Association recently submitted a series of regulatory filings to reduce administrative burdens placed on people living with ALS. The filings are in support of administrative rule changes at…
In broad terms, occupational therapy focuses on a person’s ability to perform activities of daily living—to live life to its fullest. For people with ALS, an occupational therapist (or OT)…
Our April eNewsletter is in your inbox now or you can view it online! April is Volunteer Appreciation Month and the Golden West Chapter celebrates all who have generously given…
As a young adult, Annette Uribe found herself in the role of primary caregiver as well as a primary decision-maker. When Annette was 22, her mother was diagnosed with pancreatic…
Since 1996, the Sheila Essey Award for ALS Research has been presented to acknowledge and honor an individual who is making significant contributions and breakthroughs in the search for the…
NurOwn (BrainStorm Cell Therapeutics) is an investigational therapy made up of autologous mesenchymal stromal cells secreting neurotrophic factors cells (MSC-NTF) for the potential treatment of amyotrophic lateral sclerosis (ALS) and…